Polymer Lung Surfactants
Polymer Lung Surfactants
复制标题
DOI：
10.1021/acsabm.8b00061
复制
发表时间：
2018-09-17
影响因子：
4.7
通讯作者：
Won, You-Yeon
中科院分区：
文献类型：
--
作者：
Kim, Hyun Chang;Suresh, Madathilparambil, V;Won, You-Yeon
在美国，动物源性肺表面活性剂每年挽救40000名患有新生儿呼吸窘迫综合征（NRDS）的婴儿。肺表面活性剂还具有治疗每年约19万例急性呼吸窘迫综合征（ARDS）成人患者的潜力。为此，需要修改当前疗法的性质。尽管自20世纪90年代以来，人们已经认识到目前治疗方法的局限性，但几乎没有改善。为了解决这一差距，我们的实验室一直在探索一种完全不同的方法，其中使用合成聚合物作为活性成分，而不是脂质，蛋白质或肽。这一努力导致了一个有前途的聚合物为基础的肺表面活性剂的候选人，聚（苯乙烯-b-乙二醇）（PS-PEG）聚合物纳米胶束的鉴定。PS-PEG胶束在高压下产生极低的表面张力，因为PS-PEG胶束对空气-水界面具有强亲和力。NMR测量支持PS-PEG胶束比普通聚合物胶束更少水合。使用酸吸入小鼠模型的研究证实PS-PEG肺表面活性剂是安全有效的。
Animal-derived lung surfactants annually save 40 000 infants with neonatal respiratory distress syndrome (NRDS) in the United States. Lung surfactants have further potential for treating about 190 000 adult patients with acute respiratory distress syndrome (ARDS) each year. To this end, the properties of current therapeutics need to be modified. Although the limitations of current therapeutics have been recognized since the 1990s, there has been little improvement. To address this gap, our laboratory has been exploring a radically different approach in which, instead of lipids, proteins, or peptides, synthetic polymers are used as the active ingredient. This endeavor has led to an identification of a promising polymer-based lung surfactant candidate, poly(styrene-b-ethylene glycol) (PS-PEG) polymer nanomicelles. PS-PEG micelles produce extremely low surface tension under high compression because PS-PEG micelles have a strong affinity to the air-water interface. NMR measurements support that PS-PEG micelles are less hydrated than ordinary polymer micelles. Studies using mouse models of acid aspiration confirm that PS-PEG lung surfactant is safe and efficacious.